Stefanie Ueda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefanie Ueda has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Jocelyn Chapman
University of California, San Francisco 2 Helen Diller Family Comprehensive Cancer Center San Francisco, California
9 shared publications - Lee-May Chen
University of California, San Francisco
8 shared publications - Edwin A. Alvarez
University of California, San Francisco 2 Helen Diller Family Comprehensive Cancer Center San Francisco, California
7 shared publications - Alan Ashworth
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
6 shared publications - Andrew H. Ko
University of California San Francisco, San Francisco, CA
6 shared publications - Eric A. Collisson
Human Biology, Fred Hutchinson Cancer Center
6 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures1 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Supplementary Fig 1-9 with legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures1 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Supplementary Fig 1-9 with legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Study Representativeness Table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Study Representativeness Table
- 24 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Purpose: ARID1A is frequently mutated in cancer. Motivated by the preclinical synthetic lethality between ARID1A loss and ataxia telangiectasia and Rad3-related (ATR) inhibition, we performed an investigator-initiated phase II study of the ATR inhibitor (ATRi) ceralasertib in ARID1A-deficient solid tumors (NCT03682289). Patients and Methods: This was a phase II, Simon two-stage study with a planned sample size of 29 evaluable patients. Eligible patients had locally advanced or metastatic solid tumors with measurable disease by Response Evaluation Criteria in Solid Tumors 1.1 and radiographic progression at study entry. Patients were required to have ARID1A loss as determined by immunohistochemistry analysis of tumor tissue. Patients received ceralasertib 160 mg twice daily on days 1 to 14 every 28 days. RNA sequencing (RNA-seq) and cyclic immunofluorescence were performed on tumor tissue to identify potential biomarkers of treatment response. Results: The confirmed objective response rate (ORR) was 14% among the 29 efficacy-evaluable patients. All four responses, including three complete responses, occurred in endometrioid endometrial carcinoma or ovarian clear-cell carcinoma, with an ORR of 33% and a median duration of response of 33.7 months in this subset. Including one patient with uterine carcinosarcoma who had stable disease, the ORR was 31% among the 13 patients with gynecologic malignancies. Exploratory RNA-seq analysis of pretreatment archival tumor tissue identified upregulated G2–M checkpoint and DNA double-strand break-sensing pathways in patients who responded. Immune profiling revealed tumor immune microenvironment changes associated with the response to ceralasertib. Conclusions: Ceralasertib monotherapy demonstrated promising antitumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATRis in this patient population.
- 24 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
Purpose: ARID1A is frequently mutated in cancer. Motivated by the preclinical synthetic lethality between ARID1A loss and ataxia telangiectasia and Rad3-related (ATR) inhibition, we performed an investigator-initiated phase II study of the ATR inhibitor (ATRi) ceralasertib in ARID1A-deficient solid tumors (NCT03682289). Patients and Methods: This was a phase II, Simon two-stage study with a planned sample size of 29 evaluable patients. Eligible patients had locally advanced or metastatic solid tumors with measurable disease by Response Evaluation Criteria in Solid Tumors 1.1 and radiographic progression at study entry. Patients were required to have ARID1A loss as determined by immunohistochemistry analysis of tumor tissue. Patients received ceralasertib 160 mg twice daily on days 1 to 14 every 28 days. RNA sequencing (RNA-seq) and cyclic immunofluorescence were performed on tumor tissue to identify potential biomarkers of treatment response. Results: The confirmed objective response rate (ORR) was 14% among the 29 efficacy-evaluable patients. All four responses, including three complete responses, occurred in endometrioid endometrial carcinoma or ovarian clear-cell carcinoma, with an ORR of 33% and a median duration of response of 33.7 months in this subset. Including one patient with uterine carcinosarcoma who had stable disease, the ORR was 31% among the 13 patients with gynecologic malignancies. Exploratory RNA-seq analysis of pretreatment archival tumor tissue identified upregulated G2–M checkpoint and DNA double-strand break-sensing pathways in patients who responded. Immune profiling revealed tumor immune microenvironment changes associated with the response to ceralasertib. Conclusions: Ceralasertib monotherapy demonstrated promising antitumor activity in ARID1A-deficient gynecologic malignancies. Tumor molecular and immune correlates may inform the further development of ATRis in this patient population.
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300494
Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2
PURPOSE: Combining poly ADP-ribose polymerase (PARP) and topoisomerase I inhibitors has demonstrated synergistic effects in in vivo models. This phase I trial evaluated rucaparib and irinotecan in metastatic solid tumors with homologous recombination deficiency. METHODS: This study enrolled patients in three cohorts to determine the tolerability and preliminary efficacy of (1) rucaparib 400 mg PO twice a day (days 1-7, 15-21) and irinotecan 65 mg/m2 intravenously once every 2 weeks; (2) rucaparib 400 mg PO twice a day (D1-7, 15-21) and irinotecan 100 mg/m2 once every 2 weeks; and (3) rucaparib 400 mg per os twice a day (D1-7) and irinotecan 100 mg/m2 once every 3 weeks. RESULTS: Twenty patients were enrolled: 95% with previous platinum, 40% with previous irinotecan, and 20% with previous PARP inhibitor. The maximally tolerated was determined as rucaparib 400 mg twice a day days 1-7 and irinotecan 100 mg/m2 once every 3 weeks. Four dose-limiting toxicities (all grade 3-4 neutropenia) occurred during dose escalation with only neutropenia as other grade 3-4 toxicities (25%; grade 3 [n = 3], grade 4 [n = 2]). Treatment-related grade 1-2 adverse events included neutropenia (45%), diarrhea (45%), nausea (40%), and fatigue (30%). Of 17 patients with evaluable disease, six patients (35%) derived clinical benefit (n = 2 with PR, n = 4 with stable disease for over 6 months). Three patients remained on study >1 year: two with ATM mutations (small bowel carcinoma and pancreatic neuroendocrine tumor) and one patient with a PALB2 mutation (primary peritoneal cancer). CONCLUSION: Pulse dosing of rucaparib and once every 3 weeks irinotecan was well tolerated for up to 18 months with durable responses in BRCA-, PALB2-, and ATM-mutated cancers despite progression on previous platinum.
- 1 June 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300494
Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2
PURPOSE: Combining poly ADP-ribose polymerase (PARP) and topoisomerase I inhibitors has demonstrated synergistic effects in in vivo models. This phase I trial evaluated rucaparib and irinotecan in metastatic solid tumors with homologous recombination deficiency. METHODS: This study enrolled patients in three cohorts to determine the tolerability and preliminary efficacy of (1) rucaparib 400 mg PO twice a day (days 1-7, 15-21) and irinotecan 65 mg/m2 intravenously once every 2 weeks; (2) rucaparib 400 mg PO twice a day (D1-7, 15-21) and irinotecan 100 mg/m2 once every 2 weeks; and (3) rucaparib 400 mg per os twice a day (D1-7) and irinotecan 100 mg/m2 once every 3 weeks. RESULTS: Twenty patients were enrolled: 95% with previous platinum, 40% with previous irinotecan, and 20% with previous PARP inhibitor. The maximally tolerated was determined as rucaparib 400 mg twice a day days 1-7 and irinotecan 100 mg/m2 once every 3 weeks. Four dose-limiting toxicities (all grade 3-4 neutropenia) occurred during dose escalation with only neutropenia as other grade 3-4 toxicities (25%; grade 3 [n = 3], grade 4 [n = 2]). Treatment-related grade 1-2 adverse events included neutropenia (45%), diarrhea (45%), nausea (40%), and fatigue (30%). Of 17 patients with evaluable disease, six patients (35%) derived clinical benefit (n = 2 with PR, n = 4 with stable disease for over 6 months). Three patients remained on study >1 year: two with ATM mutations (small bowel carcinoma and pancreatic neuroendocrine tumor) and one patient with a PALB2 mutation (primary peritoneal cancer). CONCLUSION: Pulse dosing of rucaparib and once every 3 weeks irinotecan was well tolerated for up to 18 months with durable responses in BRCA-, PALB2-, and ATM-mutated cancers despite progression on previous platinum.
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S25
48 An evidence-based approach to prescribing post-discharge opioids after laparotomy
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S25
Open Access48 An evidence-based approach to prescribing post-discharge opioids after laparotomy
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S28
55 If you don't use it, lose it: reducing over prescription of opioids at discharge
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S28
Open Access55 If you don't use it, lose it: reducing over prescription of opioids at discharge
- 1 March 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 120, S117
Comparison of the new and old FIGO staging systems for vulvar carcinoma: A study of 4842 patients
- 1 March 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 120, S117
Comparison of the new and old FIGO staging systems for vulvar carcinoma: A study of 4842 patients